ProteinChip Technology Reveals Distinctive Protein Expression Profiles in the Urine of Bladder Cancer Patients

Mueller, Joerg P.; Eggeling, Ferdinand von; Driesch, Dominik; Schubert, Jörg; Melle, Christian; Junker, Kerstin

doi:10.1016/j.eururo.2005.02.016

Cited by 44 publications

(29 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of these was subsequently identified as a member of the defensin family, a group of endogenous antibiotic peptides that are locally secreted in response to inflammation. Another SELDI-TOF-MS study (61) demonstrated an additional set of polypeptides (reported as m/z ratios) associated with bladder cancer that when used in a machine learning-based computer algorithm gave 80% sensitivity and 90 -97% specificity in a validation set of patient samples. Proteomics investigation of TCC tissue using 2-D electrophoresis and immunoblotting led to the recognition that adipocyte-type fatty acid-binding protein is expressed in markedly decreased amounts in TCC compared with normal transitional epithelium, and it has been proposed as an indicator of the degree of progression of the tumor (67,68), although adipocyte-type fatty acid-binding protein has not been taken forward as a potential urinary biomarker for clinical use.…”

Section: Urinary Proteomics In Cancer Diagnosismentioning

confidence: 99%

Discovery of Urinary Biomarkers

Pisitkun

Johnstone

Knepper

2006

Molecular & Cellular Proteomics

364

318

View full text Add to dashboard Cite

A myriad of proteins and peptides can be identified in normal human urine. These are derived from a variety of sources including glomerular filtration of blood plasma, cell sloughing, apoptosis, proteolytic cleavage of cell surface glycosylphosphatidylinositol-linked proteins, and secretion of exosomes by epithelial cells. Mass spectrometry-based approaches to urinary protein and peptide profiling can, in principle, reveal changes in excretion rates of specific proteins/peptides that can have predictive value in the clinical arena, e.g. in the early diagnosis of disease, in classification of disease with regard to likely therapeutic responses, in assessment of prognosis, and in monitoring response to therapy. These approaches have potential value, not only in diseases of the kidney and urinary tract but also in systemic diseases that are associated with circulating small protein and peptide markers that can pass the glomerular filter. Most large scale biomarker discovery studies reported thus far have used one of two approaches to identify proteins and peptides whose excretion in urine changes in specific disease states: 1) two-dimensional electrophoresis with mass spectrometric and/or immunochemical identification of proteins and 2) top-down mass spectrometric methods (SELDI-TOF-MS and capillary electrophoresis-MS). These studies have been chiefly in the areas of nephrology, urology, and oncology. We review these applications, focusing on two areas of progress, viz.

show abstract

Section: Urinary Proteomics In Cancer Diagnosismentioning

confidence: 99%

Discovery of Urinary Biomarkers

Pisitkun

Johnstone

Knepper

2006

Molecular & Cellular Proteomics

364

318

View full text Add to dashboard Cite

show abstract

“…Urine proteome analysis toward the discovery of bladder cancer biomarkers has been clearly demonstrated by using 2-DE/MS or SELID-TOF-MS approaches [283][284][285][286][287][288][289][290][291]. Some putative markers discovered for bladder cancer included urinary psoriasin, calreticulin (CRT), gamma-synuclein (SNCG), catechol-omethyltransferase (COMT), orosomucoid, zinc-alpha-2-glycoprotein, matrix metalloproteinase-2 (MMP-2), MMP-9, fibronectin, and their fragments [284][285][286][287][288].…”

Section: Application To Human Disease Detectionmentioning

confidence: 99%

Human body fluid proteome analysis

2006

View full text Add to dashboard Cite

The focus of this article is to review the recent advances in proteome analysis of human body fluids, including plasma/serum, urine, cerebrospinal fluid, saliva, bronchoalveolar lavage fluid, synovial fluid, nipple aspirate fluid, tear fluid, and amniotic fluid, as well as its applications to human disease biomarker discovery. We aim to summarize the proteomics technologies currently used for global identification and quantification of body fluid proteins, and elaborate the putative biomarkers discovered for a variety of human diseases through human body fluid proteome (HBFP) analysis. Some critical concerns and perspectives in this emerging field are also discussed. With the advances made in proteomics technologies, the impact of HBFP analysis in the search for clinically relevant disease biomarkers would be realized in the future.

show abstract

“…Another approach analysing changes in PTMs of urinary proteins in TCC patients concluded that these changes may provide practical information for the identification of patients with TCC at early stage [191]. SELDI-TOF has been applied in this type of cancer [192,193].…”

Section: Urinementioning

confidence: 99%

A better understanding of molecular mechanisms underlying human disease

Bermúdez-Crespo

López

2007

Proteomics Clinical Apps

View full text Add to dashboard Cite

This review summarises and discusses the degree to which proteomics is contributing to medical care, providing examples and signspots for future directions. Why do genomic approaches provide a limited view of gene expression? Because of the multifactorial nature of many diseases, proteomics enables us to understand the molecular basis of disease, not only at the organism, whole‐cell or tissue levels, but also in subcellular structures, protein complexes and biological fluids. The application of proteomics in medicine is expected to have a major impact by providing an integrated view of individual disease processes. This review describes several proteomic platforms and examines the role of proteomics as a tool for clinical biomarker discovery, the identification of prognostic and earlier diagnostic markers, their use in monitoring the effects of drug treatments and eventually find more efficient and safer therapeutics for a wide range of pathologies.

show abstract

ProteinChip Technology Reveals Distinctive Protein Expression Profiles in the Urine of Bladder Cancer Patients

Cited by 44 publications

References 31 publications

Discovery of Urinary Biomarkers

Discovery of Urinary Biomarkers

Human body fluid proteome analysis

A better understanding of molecular mechanisms underlying human disease

Contact Info

Product

Resources

About